Biocytogen has been recognized in the first tier of the 2026 Top 100 Most Innovative Chinese Pharmaceutical Companies (CPIE 100), announced at the 2026 China Pharmaceutical Innovation Top 100 Conference, held June 26–27 in Tianjin, China. The recognition reflects the company's continued innovation in antibody discovery, proprietary technology platforms, intellectual property, and its expanding portfolio of innovative antibody assets.
The China Pharmaceutical Innovation Top 100 is one of China's leading benchmarks for pharmaceutical innovation. The ranking evaluates companies across three dimensions—innovation foundation, innovation process, and innovation outcomes—using four key indicators: core patents for innovative drugs, peripheral patents for innovative drugs, clinical trial activity, and innovative drug approvals and commercialization.
Biocytogen's first-tier recognition highlights the company's continued progress in advancing proprietary technologies into differentiated antibody assets with global partnership potential. As of the end of 2025, Biocytogen held 206 granted patents and had filed 475 patent applications across 25 countries and regions. Its proprietary RenMice® platform and related core technologies have been granted 29 patents worldwide, with 57 patent applications filed, providing a strong intellectual property foundation for continued innovation and global commercialization.
In May 2026, Biocytogen introduced RenSuperTM Workstation, its next-generation AI-powered antibody discovery platform. Combining the company's proprietary RenMice® platform, an AI-driven antibody analysis engine, and a fully automated antibody production center, RenSuper Workstation offers off-the-shelf access to experimentally validated fully human antibodies against more than 1,000 therapeutic targets. Designed as a one-click therapeutic antibody discovery system, the platform transforms antibody discovery from a project-based workflow into a searchable, programmable, and scalable system.
Looking ahead, Biocytogen will continue advancing innovation across its antibody discovery platforms and expanding global collaborations as it pursues its vision of becoming the “Global Headstream of New Drugs”.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Biocytogen Contacts
Antibody assets and platforms: [email protected]
Media: [email protected]
